9/4/2014 1:00:00 AM
KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.
6/4/2014 1:00:00 AM
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
5/22/2014 1:00:00 AM
KineMed Inc. today announced the appointment of Patrick James Doyle as Executive Vice President & Chief Business Officer. Doyle joins KineMed from PPD where he most recently served as Vice President, Strategic Partnerships.
Marc Hellerstein, M.D., Ph.D., President and Chief Scientific Officer
talks about the power of Proteome Dynamics at the Personalized Medicine World Conference